STAR SPORTS MED

Star Sports Medicine surged 5.2% to HKD 151.6 in the morning session, driven by a share repurchase plan for up to 2.9 million H-shares and a 21.6% revenue increase to RMB 163.43 million in FY26 H1, though net profit dropped 26.1% to RMB 27.4 million. The stock remains 49.3% below its 52-week high of HKD 299, yet trades above its 20-day MA of HKD 134.71 but below the 60-day MA of HKD 159.84, indicating a short-term bounce amid a medium-term downtrend. However, the stock is down 29.49% year-to-date, reflecting persistent valuation concerns.

Star Sports Medicine surged in the morning session, rising 5.4% to HK$149.5 by 9:55 BJ, driven by the announcement of a proposed share buyback of up to 2.9 million H shares under a repurchase mandate. The move came after the company reported a 21.6% YoY revenue increase to RMB 163.4 million in FY26 H1, though net profit fell 26.1% to RMB 27.4 million. At HK$149.5, the stock is 50% below its 52-week high of HK$299, yet trades above the 20-day MA of HK$134.4, while still 7% below the 60-day MA of HK$160.9, with a YTD decline of 30.5%.

Tianxing Medical opened at HK$168 but plunged to HK$154 in the morning session, down 5.5%, after reporting a 26.1% YoY decline in first-half FY2026 net profit to RMB27.4 million, despite a 21.6% revenue increase to RMB163.43 million, as cost pressures weighed on earnings. The current price of HK$154 is 48.5% below the 52-week high of HK$299 but 45.3% above the 52-week low of HK$106, and has risen above its 20-day moving average of HK$135, though it remains below the 60-day average of HK$162. A previously announced plan to repurchase up to 2.9 million H-shares failed to offset the negative sentiment from the profit decline.

Star Sports Medicine surged 5.7% to close at HK$162.8 during the morning session after a volatile open, driven by its FY26 H1 revenue growing 21.6% YoY to RMB 163.43 million, though net profit fell 26.1% to RMB 27.4 million. The earnings beat some market expectations, fueling a rebound from an intraday low of HK$153.1 to a high of HK$163.5. The stock remains 45.55% below its 52-week high of HK$299 but has recovered above its MA20 (HK$134.26), with YTD losses narrowing to 24.28%. PE stands at 60.9x and PB at 5.95x. However, the stock had previously dropped nearly 5% on May 8 and faced post-listing pressure, indicating lingering downside risks.

1609.HK opened lower in the morning session at HK$145.7, down 1.1% from the prior close of HK$147.3, but staged a strong rebound, hitting an intraday high of HK$157.9, representing a 7.2% gain, and closing at HK$157.9 with a full-day range of 8.2%. The rally was driven by the company's announcement of a board meeting on August 20 to review interim results and dividend recommendations, along with a proposed 2026 share incentive scheme capped at 10% of total shares. Technically, the stock has reclaimed its MA20 (HK$133), but remains 47.2% below the 52-week high of HK$299, with a YTD decline of 26.6% and a high PE of 57.1x, though it has bounced 48.9% from the 52-week low of HK$106.